Overview
EDIT market data
Price History
EDIT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.00 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -157.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.66 – $4.54 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $441.5M · P/B 7.33 · P/S 9.39.
Company News
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M EstimateBenzinga · Aug 5, 2026, 8:37 PM
Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal DiseasesGlobenewswire Inc · Jul 14, 2026, 3:15 PM
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive GrowthGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 2, 2026, 2:30 PM
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On WednesdayBenzinga · May 27, 2026, 2:55 PM
8-K filing — Editas Medicine, Inc. (EDIT)SEC EDGAR · May 26, 2026, 8:42 PM
Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 EachBenzinga · May 26, 2026, 1:08 PM
Editas Medicine Launches Public Stock Offering to Raise CapitalBenzinga · May 26, 2026, 10:19 AM
Editas Reports Cholesterol-Lowering Results for Experimental Gene TherapyBenzinga · May 26, 2026, 10:11 AM